The Pennant Group discusses the expected EBITDA contributions throughout 2026 from its UnitedHealth/Amedisys acquisitions, highlighting a phased quarterly ramp-up following integration waves set to complete by October 2026.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Can you break out expected 2026 EBITDA contribution by quarter from the UnitedHealth/Amedisys waves?
The Pennant Group completed a significant acquisition of over 50 locations from UnitedHealth and Amedisys in October 2025, expanding their footprint in the Southeast. The integration of these operations is being executed in waves, with completion anticipated by October 2026. Management’s 2026 EBITDA guidance and commentary provide insight into the expected EBITDA ramp associated with these acquired assets.
Full-year 2026 adjusted EBITDA guidance:
$88.5 million to $94.1 million, representing a 26% increase at the midpoint compared to 2025 ($72.5 million actual adjusted EBITDA)123.
This guidance encompasses:
The EBITDA guidance is annual and not broken out explicitly by quarter. However, management describes an anticipated ramp throughout the year, particularly in H1 2026, as they transition these locations in waves14.
The UnitedHealth/Amedisys acquisitions are being transitioned in multiple waves that will complete by October 2026 (Q4 2026)4.
As with prior acquisitions (e.g., Signature Healthcare in 2024), the integration process involves some expected short-term “noise” or choppiness in EBITDA, especially during the early quarters of transition as systems and branding are converted45.
The transition includes migrating IT operating systems (Homecare Homebase), branding, and consolidating support services under Pennant’s model, which causes temporary disruption and incremental transition services costs45.
Management expects the acquired operations to progressively contribute more EBITDA each quarter as integration completes, leading to EBITDA optimization by year-end 202645.
In fact, by the end of 2026, the company is targeting normalized EBITDA margins consistent with its current mature portfolio (15%-16%), with an aspiration to reach an optimal 18% margin over time6.
The Signature Healthcare acquisition in 2024 initially had a similar integration pattern, with noted rapid improvements as local leaders were supported and elevated.
The company expresses confidence that, despite the larger scale of the UnitedHealth/Amedisys deal, the lessons learned and strong leadership teams have accelerated integration progress, supporting the EBITDA ramp throughout 202651.
The CEO and CFO emphasize a conservative approach to 2026 guidance due to transition-related inefficiencies and support costs in the early quarters, offset by strong organic and acquired asset growth over the year7.
They expect the first three quarters of 2026 to bear transition-related noise, with EBITDA growth gaining traction in Q3 and Q4, coinciding with completion of transition activities4.
This is consistent with management’s expectation that operational and EBITDA optimization will be substantially realized by October 2026, the point at which all waves will be integrated4.
2025 Q4 Home Health and Hospice adjusted EBITDA: $33.7 million, up 58.2% YOY, driven by acquisitions plus organic growth8.
2025 full year adjusted EBITDA was $72.5 million, with 2026 guidance midpoint implying ~$91 million EBITDA, reflecting ~26% growth, largely driven by contributions from UnitedHealth/Amedisys assets and organic growth across existing operations12.
No explicit quarterly breakout is provided, but the stated anticipated half-year phased integration implies modest EBITDA in Q1 and Q2 2026 from the new assets, with stronger EBITDA contributions in Q3 and Q4 2026.
Incremental costs from transition services are embedded in guidance and expected to diminish as the year progresses4.
| Quarter | EBITDA Contribution Characteristics | Supporting Commentary |
|---|---|---|
| Q1 2026 | Initial contribution; early-wave integration; transition noise expected | Transition starts; system migrations; incremental costs4 |
| Q2 2026 | Incremental ramp-up; continued operational disruption | Ongoing waves; branding transition; partial efficiencies4 |
| Q3 2026 | Significant ramp expected; closer to operational optimization | Completion nearing; efficiencies realized; EBITDA growth4 |
| Q4 2026 | Full integration; optimized contribution; continued organic growth | Wave completion (October); targets EBITDA margin expansion46 |
While The Pennant Group does not provide a precise quarterly EBITDA dollar forecast for the UnitedHealth/Amedisys acquisitions, the following financial analysis is evident from management commentary and guidance:
The adjusted EBITDA contribution from the acquisitions is expected to ramp gradually throughout 2026, with limited contribution and some transitional expense-related noise in H1.
The phased "wave" integrations will finish by October 2026 (Q4), at which point the acquired operations should be fully integrated and EBITDA performance optimized to near or above current mature margin levels (15-16%, with a longer-term goal of ~18% margin).
Full-year 2026 adjusted EBITDA guidance of $88.5 million to $94.1 million (~26% increase midpoint) clearly incorporates the UnitedHealth/Amedisys contribution plus organic growth, signaling meaningful EBITDA addition realized progressively over the year.
The ramp profile is consistent with prior acquisition experience (Signature Healthcare), augmented by lessons learned and stronger leadership teams.
Therefore, investors should anticipate modest EBITDA impact from these assets in Q1/Q2 2026, with a meaningful acceleration and near-full contribution in Q3/Q4 2026 as integration completes and operating leverage improves.
18267435 (from the provided excerpt citations)
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Cencora reports approximately 7% core growth in Q2 2026, suggesting underlying performance remains within its long-term framework despite WAC/IRA headwinds and customer losses. Management trimmed fiscal 2026 revenue guidance to 4-6%, but maintains a resilient long-term operating-income outlook supported by margin gains from mail-order conversions and ongoing OneOncology integration.
Sources used
Research questionWhat is the impact on long-term revenue and operating income growth from WAC/IRA adjustments, the loss of the oncology and grocery customers, and faster brand conversions at the large mail-order customer, given the reported core growth near 7%?
Answer outline
Twin Eagle's roughly $200 million base EBITDA is anchored in origination and logistics optimization rather than asset ownership. The earnings base appears repeatable under normal market conditions, with upside potential in volatile periods when dislocations boost margins. The expansion with Expand is expected to lift annual earnings toward the mid- to high-$300 millions within the next two years, supported by a large, high-retention customer base and recurring commercial relationships.
Sources used
Research questionWhat drives Twin Eagle's $200 million EBITDA—origination versus storage/transit spreads—and what is the expected year-to-year variability?
Answer outline
Peet's K-Cups shifts from U.S. Coffee to JDE Peet’s following the April close distort Q2 segment comparisons by moving Peet’s economics into the JDE Peet’s segment and making U.S. Coffee appear weaker. Management expects the back-half reversal to be neutral for enterprise earnings, with U.S. Coffee benefiting and JDE Peet's facing a corresponding headwind, and notes the Q2 result may represent a 2026 high-water mark for JDE Peet’s.
Sources used
Research questionHow did the acquisition-related reporting shift for Peet’s K-Cups between U.S. Coffee and JDE Peet’s affect Q2 segment comparisons, and what does management expect for the back-half earnings impact at the enterprise level?
Answer outline
TransDigm Group reports year-to-date margin pressure from acquisition-related dilution exceeding 200 basis points, with Q3 EBITDA margin at 52.8% and a conservative Q4 outlook as acquisitions remain early in ownership. Management maintains a modest, constant-mix margin improvement target of roughly 1% to 1.5% year over year, while noting only small mix headwinds and ROE-related headwinds without quantifying them.
Sources used
Research questionWhat is the year-to-date margin performance and what is expected for Q4 margins given acquisitions' dilution and mix and ROE-related headwinds?
Answer outline
Mastercard management expects Q3 rebates to be slightly higher than Q2 as a share of network assessments, driven by timing and deal performance, with a strong deal pipeline supporting execution. The BVNK acquisition is anticipated to close in Q3 with minimal net revenue impact but some operating expense, highlighting ongoing concentration on future flexibility.
Sources used
Research questionWhat did management say about Q3 rebates and incentives outlook?
Answer outline
Martin Marietta raises 2026 revenue guidance to 7.2B–7.4B, aided by New Frontier and Quikrete contributions; management expects a cleaner back half as fair-value step-ups fade and volumes remain strong.
Sources used
Research questionWhat are the puts and takes behind the updated 2026 revenue guidance, including contributions from New Frontier and Quikrete, and related margins and pace?
Answer outline
Amphenol's raised guidance for the CommScope acquisition points to a profitability path built on operating leverage and disciplined cost management rather than a simple top-line boost. The company emphasizes that the margin uplift derives from higher sales conversion, SG&A and Opex discipline, and operational execution, with acquisition-related amortization still leaving the business with a strong, mid-20s percent operating margin on an overall basis.
Sources used
Research questionWalk through the margin and earnings upside from the CommScope acquisition: is the improvement driven by operating leverage, gross margin expansion, or other factors, and how does amortization affect profitability outlook?
Answer outline
Aon plc reports Q2 2026 Commercial Risk growth was restrained by M&A services, with organic revenue up 5% as the quarter faced a headwind from muted M&A activity. Management signaled a stronger second-half pipeline, noting >60% higher announced transaction volumes and that M&A should become a tailwind for the year, supporting the company’s mid-single-digit organic growth guidance and improved visibility into full-year revenue.
Sources used
Research questionHow large was the M&A services drag in Commercial Risk in Q2, and what is the expected contribution from the stronger second-half pipeline to full-year growth?
Answer outline
Thermo Fisher's Q2 2026 results show a mixed yet constructive performance: Clario boosts reported growth via acquisitions (not organic), Patheon posts modest gains with a timing-driven second-half uplift, and PPD demonstrates strong clinical-research momentum despite a six-month authorization-to-revenue lag. Management reaffirmed guidance as acquisitions bolster full-year results across segments and supports guidance improvements.
Sources used
Research questionCould you share more color on PPD, Clario, and Patheon performance in Q2, including bookings, revenue growth, and contribution to the overall results?
Answer outline
TransDigm's management indicates the destocking noise in distribution is largely behind them, with POS signals supporting a tailwind as inventories clear. They outline a margin framework beyond 2026, highlighting near-term dilution from acquisitions but a continued base-margin expansion through 2027–2028 as integration progresses.
Sources used
Research questionIs the channel destock ending and how will margins evolve beyond 2026, including potential expansion in 2027–2028 amid acquisitions?
Answer outline
Elevance Health outlines a cautious 2H 2026 outlook for Medicaid, keeping the full-year margin at -1.75% and signaling only incremental improvement in the back half as rate updates and cost actions mature. Exits from markets lacking sustainable economics, including a DC exit and 12–18 month plans for additional markets, are framed as portfolio discipline rather than a driver of the near-term margin.
Sources used
Research questionGiven the Medicaid margin trajectory, quantify the potential exits relative to the $57 billion Medicaid revenue run rate and clarify whether exits are driven by work requirements or other state discussions, and how the second-half margin may differ?
Answer outline
The discussion highlights an increased contribution from acquisitions in the 2026 outlook, leading to a modest reduction in organic growth forecasts, primarily affecting the Lab segment due to early-year headwinds and macro caution, with Industrial showing signs of cautious optimism.
Sources used
Research questionWhat explains the higher M&A contribution to the 2026 outlook, and is the organic growth outlook modestly reduced, and if so, is the adjustment concentrated in Lab, Industrial, or both?
Answer outline
Dafinchi